EXINI Diagnostics AI Software
CE Mark cleared AI diagnostic software for medical imaging
Software · OtherCompany source
Company profile
About EXINI Diagnostics AB
EXINI Diagnostics AB is a medical imaging software company specializing in artificial intelligence solutions for nuclear medicine and radiology. As a subsidiary of Lantheus Holdings, EXINI develops advanced diagnostic tools that leverage AI to automate and enhance the interpretation of medical imaging studies. The company's software platforms are designed to assist healthcare professionals in analyzing complex imaging data, particularly in nuclear medicine applications. EXINI's technology aims to improve diagnostic accuracy, reduce interpretation time, and support clinical decision-making across various medical imaging modalities. The company has achieved regulatory clearances including CE Mark approval for its diagnostic solutions, enabling deployment across European healthcare markets. EXINI's products serve radiologists, nuclear medicine physicians, and other imaging specialists in hospitals and diagnostic imaging centers. The company focuses on developing evidence-based AI solutions that integrate into existing clinical workflows and imaging infrastructure.
Company description EXINI Diagnostics AB official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at EXINI Diagnostics AB?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Diagnostic Imaging Centers
- Health Systems
- Hospitals
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsEurope
Company sourceOfficial website
Company milestones
Platform expansion
Received CE Mark clearance for diagnostic software
Partnerships
Recorded partners
- Lantheus Holdings (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from EXINI Diagnostics AB
Recent articles published on EXINI Diagnostics AB's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.